Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.56, $0.33 better than the analyst estimate of $0.23. Revenue for the quarter came in at $122.7 million versus the consensus estimate of $111.77 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of $462.4 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.